Type 1 diabetes (T1D) is a chronic autoimmune disease that in 2022 affected approximately 8.75 million individuals worldwide. T1D is characterized by the loss of pancreatic beta-cells responsible for producing insulin, a fundamental hormone that regulates blood glucose levels. Patients with T1D require lifelong insulin replacement through multiple daily insulin injections or insulin pump therapy. However, these therapies don’t fully restore glycemic control and don’t prevent T1D long-term complications such as neuropathy, retinopathy, kidney disease, stroke, macrovascular problems and foot damage. Pancreatic islet transplantation has emerged as a promising therapy; however, its clinical deployment via portal vein infusion triggers an immediate inflammatory response that hinders its curative potential.